Q3 Earnings Estimate for LMAT Issued By Barrington Research

Key Points

• Barrington Research has raised its Q3 2025 earnings per share estimate for LeMaitre Vascular to $0.57, up from $0.56, while maintaining an "Outperform" rating and a $95.00 price target on the stock.
• LeMaitre Vascular recently announced a quarterly dividend of $0.20 per share, set to be paid on September 4th, representing an annualized yield of 0.8%.
• Insider trading activity includes CEO George W. Lemaitre selling 76,868 shares valued at over $6.5 million, which constitutes a 4.10% decrease in his ownership position.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) - Stock analysts at Barrington Research lifted their Q3 2025 earnings per share estimates for LeMaitre Vascular in a research report issued on Wednesday, August 6th. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will post earnings per share of $0.57 for the quarter, up from their previous estimate of $0.56. Barrington Research has a "Outperform" rating and a $95.00 price target on the stock. The consensus estimate for LeMaitre Vascular's current full-year earnings is $1.94 per share. Barrington Research also issued estimates for LeMaitre Vascular's Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.25 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.63 EPS, Q4 2026 earnings at $0.65 EPS, FY2026 earnings at $2.58 EPS and FY2027 earnings at $2.94 EPS.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The business had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. During the same quarter in the previous year, the business earned $0.52 earnings per share. The company's revenue for the quarter was up 15.0% compared to the same quarter last year.

Separately, Cantor Fitzgerald boosted their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $98.00.

LeMaitre Vascular Trading Down 2.1%

Shares of NASDAQ:LMAT traded down $1.98 during trading hours on Friday, hitting $92.28. 149,596 shares of the company's stock traded hands, compared to its average volume of 146,164. LeMaitre Vascular has a 1 year low of $71.42 and a 1 year high of $109.58. The business has a fifty day moving average price of $83.35 and a 200-day moving average price of $86.50. The firm has a market capitalization of $2.09 billion, a P/E ratio of 44.80, a price-to-earnings-growth ratio of 2.37 and a beta of 0.79. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 13.83.

Hedge Funds Weigh In On LeMaitre Vascular

A number of large investors have recently bought and sold shares of LMAT. JPMorgan Chase & Co. raised its stake in LeMaitre Vascular by 45.9% in the fourth quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier's stock worth $13,590,000 after buying an additional 46,430 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in LeMaitre Vascular by 239.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 9,833 shares of the medical instruments supplier's stock worth $906,000 after buying an additional 6,937 shares in the last quarter. Alliancebernstein L.P. raised its stake in LeMaitre Vascular by 6.0% in the fourth quarter. Alliancebernstein L.P. now owns 22,584 shares of the medical instruments supplier's stock worth $2,081,000 after buying an additional 1,287 shares in the last quarter. Franklin Resources Inc. raised its stake in LeMaitre Vascular by 8.2% in the fourth quarter. Franklin Resources Inc. now owns 13,678 shares of the medical instruments supplier's stock worth $1,260,000 after buying an additional 1,032 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in LeMaitre Vascular by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock worth $50,711,000 after buying an additional 7,737 shares in the last quarter. Institutional investors own 84.64% of the company's stock.

Insider Activity

In related news, CEO George W. Lemaitre sold 100,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the transaction, the chief executive officer owned 1,727,003 shares of the company's stock, valued at $161,492,050.53. The trade was a 5.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 200,000 shares of company stock valued at $17,907,857 in the last ninety days. 9.50% of the stock is currently owned by insiders.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be issued a $0.20 dividend. The ex-dividend date is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular's payout ratio is presently 38.83%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.